Previous Close | 33.64 |
Open | 33.02 |
Bid | 32.63 x 50000 |
Ask | 33.61 x 50000 |
Day's Range | 33.00 - 33.02 |
52 Week Range | 22.35 - 34.48 |
Volume | |
Avg. Volume | 191 |
Market Cap | 64.234B |
Beta (5Y Monthly) | 0.29 |
PE Ratio (TTM) | 54.10 |
EPS (TTM) | 0.61 |
Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
Forward Dividend & Yield | 0.36 (1.08%) |
Ex-Dividend Date | Sept 27, 2024 |
1y Target Est | N/A |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.